The human ROSI gene, which possibly encodes a growth factor receptor, was found to be expressed in human tumor cell lines. In a survey of 45 different human cell lines, we found ROSI to be expressed in glioblastoma-derived cell lines at high levels and not to be expressed at all, or expressed at very low levels, in the remaining cell lines. The ROSI gene was present in normal copy numbers in all cell lines that expressed the gene. However, in one particular glioblastoma line, we detected a potentially activating mutation at the ROSI locus. Southern and RNA Blot Analysis. Southern blot analysis was done as described (13) . RNA for blotting was isolated by the guanidinium/cesium chloride method and was subsequently purified on oligo(dT) columns (11) . RNA blotting was done essentially as described (14). For hybridization, the same ROS1 probe synthesized by Sp6 RNA polymerase and described was used. The RNA blot was hybridized for 36 hr at 62°C in 50%6 formamide/5 x standard saline citrate (SSC) (lx SSC is 0.15 M sodium chloride/0.015 M sodium citrate)/ 10 mM EDTA/10 ,ug of carrier DNA per ml/5 x Denhardt's solution (lx Denhardt's solution is 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin), and washed in 0.1 x SSC/0.1% NaDodSO4 once for 2 min at room temperature and four times for 30 min at 64°C. RNase (12). The RNA hybrids protected from nuclease digestion were subsequently analyzed on denaturing acrylamide gels. Fig. 1 shows, as an example, the analysis of RNA from six 9270
established from a normal human glial cell. In most glioblastoma cell lines, the ROSI-encoded transcript was found to be 8.3 kilobases (kb) in size. Upon analysis of the ROSI locus by Southern blotting, an aberrant configuration due to a rearrangement in sequences encoding the putative extracellular domain, was seen in one particular glioblastoma cell line.
MATERIALS AND METHODS
ROSI Expression Studies. Total RNA from various human tumor cell lines and tissues was prepared by the guanidinium/ cesium chloride method (10) . Human placenta was obtained from elective cesarean sections and superficially normal brain tissue (temporal lobe) from a patient undergoing surgery for epilepsy. The quantity of RNA was determined by measurements of the optical density, and the quality and quantity of the RNA preparations were verified on glyoxal gels (11) . Twenty micrograms of total RNA was hybridized overnight at 520C to =1 fmol of 32P-labeled RNA transcript produced by Sp6 RNA polymerase (specific activity, 8 X 1 dpm/pmol) as described (12) . The hybridization mixture was diluted 10-fold with buffer containing 50 mM sodium acetate (pH 4.5)/2 mM EDTA/100 mM NaCl to a final volume of 300 pl and treated with 10 units of RNase T2 for 1 hr at 30'C. The nucleic acids were precipitated with ethanol and analyzed on a 5% acrylamide gel Southern and RNA Blot Analysis. Southern blot analysis was done as described (13) . RNA for blotting was isolated by the guanidinium/cesium chloride method and was subsequently purified on oligo(dT) columns (11) . RNA blotting was done essentially as described (14) . For hybridization, the same ROS1 probe synthesized by Sp6 RNA polymerase and described was used. The RNA blot was hybridized for 36 hr at 62°C in 50%6 formamide/5 x standard saline citrate (SSC) (lx SSC is 0.15 M sodium chloride/0.015 M sodium citrate)/ 10 mM EDTA/10 ,ug of carrier DNA per ml/5 x Denhardt's solution (lx Denhardt's solution is 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin), and washed in 0.1 x SSC/0.1% NaDodSO4 once for 2 min at room temperature and four times for 30 min at 64°C.
RESULTS
We previously reported the isolation of a cDNA corresponding to the transcript of an activated ROS1 gene, mcf3 (1) . A portion of this cDNA encoding amino acids 140-295 was subcloned into pSp65, a vector containing a Sp6 RNA polymerase promoter (12 (12) . The RNA hybrids protected from nuclease digestion were subsequently analyzed on denaturing acrylamide gels. Fig. 1 shows, as an example, the analysis of RNA from six (Fig. 1 , lanes 5-10). Thus ROSJ transcripts are presented in the tested glioblastoma lines. As can be seen in Fig. 1 , the protected probe resolved into a doublet on denaturing acrylamide gels. This was reproducibly observed with RNAs from all cell lines that protected this probe. The appearance of this doublet might either reflect a heterogeneity in the mcf3-and ROSI-encoded mRNA or might be an artifact due to strong secondary structures within the protected fragment.
The intensity of the band on the autoradiogram corresponding to the protected fragment can be used to quantify the amount of ROSJ transcripts in the tested RNA. For standardization, we used RNA from cell line MCF-7-3-7 and determined the counts present in the protected fragment after analysis by scintillation counting. Five micrograms of total RNA from MCF-7-3-7 cells protected 5000 dpm of the labeled probe (specific activity, 8 .107 dpm/pmol) or 0.06 fmol; 0.06 fmol corresponds to 50 pg of the 2.5-kb mcf3-encoded mRNA. Assuming that hybridization went essentially to completion, 50 pg of mcf3 mRNA was present in 5 ,ug of the total RNA. Assuming that 2% of total RNA is mRNA, this amount of mcf3 mRNA represents 0.05% of the mRNA; and assuming 400,000 mRNA molecules per cell, this amount would correspond to =200 molecules of mcf3-encoded 
In addition to glioblastoma cell lines, four other cell lines (TCCSUP, VM-CUB-2, 734B, and 8387) expressed detectable levels ofROSI transcripts, albeit at low levels, estimated to correspond to <1 transcript per cell. We did not find detectable levels of ROSI expression in the remaining 28 cell lines, including SN, a cell line established from normal human glial cells; nor did we detect ROSI expression in the two analyzed tissues, placenta and brain.
We have previously shown that the human ROSJ gene can be activated by either deletion of the putative extracellular domain and/or by amplification (1) . It was therefore of interest to determine whether the ROSI genes in the human tumor cell lines that express ROSI are present in normal copy number and in normal configuration. In all Southern blots the fragments detected by the ROSI probe were of similar intensities in placental and tumor DNAs, indicating ROSI genes in the tumor DNAs to be present in normal copy number. To study potential rearrangements, we confined our analysis of the genomic ROSI DNA to the part encoding the junction of the putative extracellular and transmembrane domains. For Southern blotting, we used a genomic EcoRI fragment 5.2 kb in length containing three exons that encode 70 amino acids of the putative extracellular domain, the potential transmembrane domain, and 42 amino acids of the putative intracellular domain (1, 15) (see diagram at bottom of Fig. 2) . In placental DNA, this probe hybridized mainly to a 9.5-kb BamHI fragment (Fig. 2, lane 1) . The position of this fragment within the ROSI locus is depicted in the diagram at the bottom of Fig. 2 . A fragment identical in size was seen in the DNAs from all tested cell lines with the exception of cell line U-118 MG, where a 20-kb fragment was detected (Fig. 2) ; U-118 MG is a cell line derived from a glioblastoma and contains 10 ROSI transcripts per cell. To exclude that altered mobility of this fragment was due to a restriction 3 4 567 Proc. Nati. Acad. Sci. USA 84 (1987) endonuclease-fragment length polymorphism, the same probe was used for Southern blot analysis of DNA digested with a different restriction enzyme, HindIII. In placental DNA and DNA from six other cell lines, two fragments, 1.5 kb and 5.5 kb, were recognized by this probe (Fig. 3) . In DNA from U-118 MG cells, the common 1.5-kb fragment and an unusual 2.25-kb fragment were seen (Fig. 3, lane 6 ). This demonstrates that the ROSJ gene in cell line U-118 MG DNA has an unusual conformation and is probably rearranged. Further support of this conclusion is the fact that in cell line U-118 MG DNA we detected only the aberrant DNA fragments, demonstrating that U-118 MG cells are homozygous for the altered ROSI gene. Additional Southern blotting data with cDNA probes indicate that at least some of the sequences encoding the putative extracellular domain are missing from cell line U-118 MG (data not shown).
Southern blot analysis allowed us to map the point of divergence between the placental and U-118 MG ROSI alleles within the 5.2-kb EcoRI fragment. Prolonged exposure of the Southern blots shown in Fig. 2 revealed a second BamHI fragment that was 10 kb in length and common to all cell lines except cell line U-118 MG (data not shown). The position of this BamHI fragment within the ROS) locus is shown in the diagram at the bottom of Fig. 2 . In U-118 MG DNA, BamHI fragments of 9.5 kb and 10 kb are both altered; the 1.5-kb HindIII fragment is intact, whereas the 5. (Fig. 4, lanes 2, 4, and 5 ). In the fourth glioblastoma cell line, U-118 MG, which contains an aberrant configuration of the ROSI gene, a smaller 4-kb ROSI transcript, is seen (Fig. 4, lane 3 ). 
DISCUSSION
We have found expression of the ROSJ gene in human tumor cell lines. In cell lines established from glioblastomas we frequently detected ROSJ transcripts ranging from below one transcript to 60 transcripts per cell. By contrast, we found only low levels of ROSJ transcripts (below one transcript per cell) in 4 out of 32 other cell lines. The weakly positive cell lines originated from two bladder carcinomas, one breast carcinoma, and one osteosarcoma. In the remaining cell lines, levels of ROS) transcripts were below our detection limit. In a similar survey of human tumor cell lines, other workers failed to detect expression of ROSJ in any lines (16) , although that survey may not have included glioblastoma cells. Moreover, we see no expression of a ROSJ gene in normal brain tissue. Thus the high level of ROSJ expression in glioblastomas seems specific.
A transcript in low abundance that hybridizes to a v-ros probe has been previously reported in RNA from kidneys of 7-to 14-day-old chicken. Due to RNA degradation, the size of this transcript could not be determined (17) . Discovery of cells that express a ROSJ gene in abundance has allowed us to determine the size of the ROSJ transcript. As determined by RNA blotting, the size of the ROSJ-encoded mRNA in three glioblastoma lines was found to be 8.3 kb and the mRNA has, thus, the potential to encode a large protein.
Preliminary immunoprecipitation studies indicate this is the case (S.S., unpublished work). The ROSI transcript in one other glioblastoma cell line, U-118 MG, was found to be 4 kb. As determined by Southern blotting, the ROSI locus ofU-118 MG does have an aberrant configuration and therefore was expected to produce an altered ROSI transcript.
Southern blot analysis indicated that ROSI was present in normal copy number in all tumor cell lines expressing the gene. However, an aberrant ROSI locus was found in one of the glioblastoma cell lines, U-118 MG. The point of divergence between the normal and U-118 MG ROSI genes was located to that portion of ROSI that encodes the junction between the putative extracellular and transmembrane domains. Our analysis indicated that sequences downstream from the point of divergence were intact. This region encodes the putative intracellular domain of ROSI. However, at least part of ROSI encoding putative extracellular sequences are missing in U-118 MG DNA, and preliminary data indicate that U-118 MG cells do produce high levels of an altered ROSI-encoded protein (S.S., unpublished work). Interestingly, the point of rearrangement in U-118 MG DNA is very close to the point of rearrangement that created the mcf3 gene. In mcf3, this leads to deletion of all but eight amino acids of the putative extracellular domain of ROSJ (1) . Loss of the putative extracellular domain is also seen in v-ros (3). Thus deletions of this domain may be an important event in the activation of the oncogenic potential of the ROSI gene.
Presently, we cannot be sure of the contribution of ROSI expression to the pathogenesis of glioblastomas, although several observations suggest a possible role. First, expression of ROSI, a potential oncogene, appears specific to glioblastomas. We do not see expression of ROSI in normal brain RNA. Second, one glioblastoma cell contains in all likelihood an "activating" deletion within the ROSI gene and is homozygous for this mutation. For these reasons we propose that ROSI expression contributes to the development of glial tumors. ROSI is not the only potential oncogene expressed in this cell type. The epidermal growth factor receptor (EGFR) gene is frequently amplified and expressed at high levels in primary human glioblastomas, and an aberrant configuration of the EGFR gene has been seen in one particular tumor of glial origin (18) .
Sequence data strongly suggest that ROSI is a membranespanning protein and therefore specifies an extracellular antigen. Thus, antibodies recognizing the putative extracellular domain might be clinically useful in diagnosis or imaging. Moreover, because ROS) does not seem to be ubiquitously expressed, such antibodies might also find application in the specific treatment of tumors of glial origin.
